https://www.selleckchem.com/products/sr-4835.html
Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium and a causative agent of tuberculosis (T, a disease that kills more than 1.5 million people worldwide annually. One of the main reasons for this high mortality rate is the evolution of new Mtb strains that are resistant to available antibiotics. Therefore, new therapeutics for TB are in constant demand. Here we report the development of such inhibitors that target two DNA replication enzymes of Mtb, namely DnaG primase and DNA gyrase, which share a conserved TOPRIM fold near t